Clinical Trials

19 enrolled

Other solid neoplasm

Solid Tumors

NCT02110355 2021-03-26

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

31 enrolled

Melanoma, Neoplasms

NCT02703571 2020-12-21

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

95 enrolled

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

113 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01938443 2019-07-12

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

Other solid neoplasmThoracic

34 enrolled

Mesothelioma, Neoplasms

NCT02027961 2019-05-17

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

68 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma, Neoplasm Metastasis

NCT01231594 2019-03-22

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

214 enrolled

Neoplasms

NCT02016729 2019-02-27

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Other hematologic neoplasm

36 enrolled

Neoplasms, Leukemia, Myeloid, Acute

NCT02258607 2019-02-01

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

21 enrolled

Thoracic

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

NCT02447939 2018-09-14

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Melanoma

NCT02939846 2018-09-14

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

Neoplasms

NCT02065063 2018-06-01

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

28 enrolled

Melanoma, Neoplasms

NCT01767454 2017-11-14

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

38 enrolled

Melanoma

NCT00687622 2017-11-13

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

206 enrolled

Melanoma, Neoplasms

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

240 enrolled

BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01192165 2017-11-13

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

169 enrolled

Neoplasms

NCT01324258 2017-11-13

Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors

19 enrolled

GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

NCT01371487 2017-11-13

GSK1120212 Food-effect Study

40 enrolled

Neoplasms

NCT01387204 2017-11-13

Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212

6 enrolled

Neoplasms

NCT01416337 2017-11-13

Absolute Bioavialability of GSK1120212

6 enrolled

Neoplasms

NCT01428427 2017-11-13

Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors

Other hematologic neoplasm

31 enrolled

Leukemia

NCT01476137 2017-11-13

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

335 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT01647659 2017-11-13

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

18 enrolled

Neoplasms

NCT01658553 2017-11-13

A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212

60 enrolled

Neoplasms

NCT00955773 2017-11-09

Cancer

64 enrolled

Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT02538627 2017-09-05

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

GastrointestinalHead & NeckThoracic

5 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms

NCT01248858 2017-05-09

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

69 enrolled

Neoplasms

NCT01287546 2017-02-15

A Study of LY2875358 in Participants With Advanced Cancer

117 enrolled

Advanced Cancer

NCT02292732 2016-01-26

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

Neoplasms

NCT01938456 2014-07-28

Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer